WA Spotlight on Argenica Therapeutics
27 October 2021
The MTPConnect WA Life Sciences Innovation Hub invites you to join the WA MTP Sector Spotlight Series event in November, featuring Argenica Therapeutics Limited.
Our monthly breakfast series is an opportunity for representatives from across the MTP sector to connect, collaborate and learn about upcoming opportunities, and hear the stories and successes of WA organisations developing health and medical innovations.
The event will feature Perth-based Argenica Therapeutics Limited (ASX:AGN), a company developing novel neuroprotective therapeutics to reduce brain damage after stroke.
Every 19 minutes someone in Australia will suffer a new stroke. Globally, there were 13 million people who experienced a stroke for the first time in their lives in 2019. When a stroke strikes, it can cause lasting brain damage, long term disability, and even death. Protecting the brain is crucial for improving patient outcomes and recovery.
Based on research from The University of Western Australia and the Perron Institute for Neurological and Translational Science, Argenica’s lead candidate ARG-007 aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimise the impact of these conditions and improve patient recovery.
Argenica’s CEO Dr Liz Dallimore with COO and Executive Director Dr Samantha South will discuss the development and commercialisation plans for the company’s novel neuroprotective therapeutic, how it will fit within current stroke treatment plans, the importance of having a differentiated approach – and clearly communicating with investors. They will also take questions from the audience.
Join us over a light breakfast at the Harry Perkins Institute of Medical Research.
Details:
- Tuesday 30 November 2021
- 7:30am-9:00am AWST
- Auditorium (ground floor) at Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands WA